Immunotherapy for the prevention of high-risk oral disorders malignant transformation : the IMPEDE trial
BACKGROUND: Oral Potentially Malignant Disorders (OPMD) have a non-negligible malignant transformation rate of up to 8%. Loss of heterozygosity (LOH) in critical chromosomal loci has proven to be the most effective marker in defining the risk of transformation and it is found in about 28% of OPMD and may therefore identify patients carrying higher risk. To date, clinical management of OPMD is limited to surgical excision and clinical surveillance, which however do not fully prevent oral cancer development. Immune system has been shown to play a key role in transformation surveillance mechanism and an immunosuppressive imbalance may be responsible for progression to cancer. Given all these considerations, we designed a clinical trial with the aim to prevent OPMD neoplastic transformation and revert the LOH status.
METHODS: This is a phase II, open label, single arm, multicentric trial involving Italian referral centres and expected to enrol 80 patients out of a total of 175 screened. Patients who meet all inclusion criteria and test positive for LOH after an incisional biopsy of the OPMD will undergo a short course of immunotherapy with 4 administration of avelumab. After 6 months since treatment start, resection of the entire OPMD will be performed and LOH assessment will be repeated. The follow-up for malignant transformation and safety assessment will last 30 months from the end of treatment, for a total planned study duration of approximately 5.5 years.
DISCUSSION: Restoring the activity of immune system through checkpoint inhibitor may play a crucial role against malignant transformation of OPMD by reverting the balance in favour of immune control and preventing cancer occurrence.
TRIAL REGISTRATION: This trial was prospectively registered in ClinicalTrials.gov as NCT04504552 on 7th August 2020.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
BMC cancer - 21(2021), 1 vom: 17. Mai, Seite 561 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gurizzan, Cristina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.10.2021 Date Revised 18.10.2021 published: Electronic ClinicalTrials.gov: NCT04504552 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12885-021-08297-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325522227 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325522227 | ||
| 003 | DE-627 | ||
| 005 | 20231225192624.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-021-08297-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1085.xml |
| 035 | |a (DE-627)NLM325522227 | ||
| 035 | |a (NLM)34001010 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gurizzan, Cristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunotherapy for the prevention of high-risk oral disorders malignant transformation |b the IMPEDE trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2021 | ||
| 500 | |a Date Revised 18.10.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04504552 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Oral Potentially Malignant Disorders (OPMD) have a non-negligible malignant transformation rate of up to 8%. Loss of heterozygosity (LOH) in critical chromosomal loci has proven to be the most effective marker in defining the risk of transformation and it is found in about 28% of OPMD and may therefore identify patients carrying higher risk. To date, clinical management of OPMD is limited to surgical excision and clinical surveillance, which however do not fully prevent oral cancer development. Immune system has been shown to play a key role in transformation surveillance mechanism and an immunosuppressive imbalance may be responsible for progression to cancer. Given all these considerations, we designed a clinical trial with the aim to prevent OPMD neoplastic transformation and revert the LOH status | ||
| 520 | |a METHODS: This is a phase II, open label, single arm, multicentric trial involving Italian referral centres and expected to enrol 80 patients out of a total of 175 screened. Patients who meet all inclusion criteria and test positive for LOH after an incisional biopsy of the OPMD will undergo a short course of immunotherapy with 4 administration of avelumab. After 6 months since treatment start, resection of the entire OPMD will be performed and LOH assessment will be repeated. The follow-up for malignant transformation and safety assessment will last 30 months from the end of treatment, for a total planned study duration of approximately 5.5 years | ||
| 520 | |a DISCUSSION: Restoring the activity of immune system through checkpoint inhibitor may play a crucial role against malignant transformation of OPMD by reverting the balance in favour of immune control and preventing cancer occurrence | ||
| 520 | |a TRIAL REGISTRATION: This trial was prospectively registered in ClinicalTrials.gov as NCT04504552 on 7th August 2020 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a LOH | |
| 650 | 4 | |a Malignant transformation | |
| 650 | 4 | |a Oral cancer | |
| 650 | 4 | |a Oral potentially malignant disorder | |
| 650 | 4 | |a Prevention | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a CD274 protein, human |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a avelumab |2 NLM | |
| 650 | 7 | |a KXG2PJ551I |2 NLM | |
| 700 | 1 | |a Lorini, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Paderno, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Tomasoni, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Zigliani, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Bozzola, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Ardighieri, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Battocchio, Simonetta |e verfasserin |4 aut | |
| 700 | 1 | |a Bignotti, Eliana |e verfasserin |4 aut | |
| 700 | 1 | |a Ravaggi, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Romani, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a De Cecco, Loris |e verfasserin |4 aut | |
| 700 | 1 | |a Serafini, Mara Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Miceli, Rosalba |e verfasserin |4 aut | |
| 700 | 1 | |a Bardellini, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Majorana, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Piazza, Cesare |e verfasserin |4 aut | |
| 700 | 1 | |a Bossi, Paolo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d 2001 |g 21(2021), 1 vom: 17. Mai, Seite 561 |w (DE-627)NLM111431948 |x 1471-2407 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:1 |g day:17 |g month:05 |g pages:561 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12885-021-08297-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 1 |b 17 |c 05 |h 561 | ||